European stocks gained as investor sentiment received a boost from better-than-expected US personal spending data, overshadowing plans by President Donald Trump to slap tariffs on patented drugs. The Stoxx Europe 600 Index rose  at the close. The healthcare sector erased earlier losses to gain 0.1% after Trump said he plans a 100% duty on patented drugs effective Oct. 1, unless the producer is building a manufacturing plant in the US. Novo Nordisk A/S fell  and Zealand Pharma A/S retreated . Most Read fr ...